

## CORRECTION


# Correction: Induced pluripotent stem cell-derived monocytic cell lines from a NOMID patient serve as a screening platform for modulating NLRP3 inflammasome activity

Ryosuke Seki, Akira Ohta, Akira Niwa, Yoshinori Sugimine, Haruna Naito, Tatsutoshi Nakahata, Megumu K. Saito

The affiliation for the third author is incorrect. Akira Niwa is not affiliated with #2 but with #1: Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

## Reference

1. Seki R, Ohta A, Niwa A, Sugimine Y, Naito H, Nakahata T, et al. (2020) Induced pluripotent stem cell-derived monocytic cell lines from a NOMID patient serve as a screening platform for modulating NLRP3 inflammasome activity. PLoS ONE 15(8): e0237030. <https://doi.org/10.1371/journal.pone.0237030> PMID: 32810141



## OPEN ACCESS

**Citation:** Seki R, Ohta A, Niwa A, Sugimine Y, Naito H, Nakahata T, et al. (2021) Correction: Induced pluripotent stem cell-derived monocytic cell lines from a NOMID patient serve as a screening platform for modulating NLRP3 inflammasome activity. PLoS ONE 16(4): e0249807. <https://doi.org/10.1371/journal.pone.0249807>

**Published:** April 5, 2021

**Copyright:** © 2021 Seki et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.